Get informed when a big investor buys or sells
+ FollowOvervalued by 180.9% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $1.61 Billion |
|---|---|
| Enterprise Value | $1.68 Billion |
| Earnings per Share | $-1.41 |
| Beta | 0.25 |
| Outstanding Shares | 123,200,000 |
| P/E Ratio | -9.07 |
|---|---|
| PEG | 49.91 |
| Price to Sales | - |
| Price to Book Ratio | 1.63 |
| Enterprise Value to Revenue | 42.59 |
| Enterprise Value to EBIT | -9.66 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.12 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Jiangsu gdk Biotechnology Co., Ltd. operates as a biotechnology firm specializing in the comprehensive research, development, manufacturing, and commercialization of human vaccines, alongside providing related services. Its current portf...